Early-Stage lung blood pressure drug trial halted
NCT ID NCT05339087
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either riociguat or a placebo for 24 weeks. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carl Gustav Carus University Hospital at the TU Dresden, Medical Department I, Center for PH
Dresden, Germany
-
Centre de référence des Maladies Auto-Immunes Systémiques rares du Nord et Nord-Ouest (CeRAINO) Service de Médecine Interne et Immunologie Clinique Hôpital Claude Huriez, CHU
Lille, 59037, France
-
Centre for Pulmonary Hypertension at the Thoraxklinik Heidelberg, Heidelberg University Hospital Heidelberg
Heidelberg, 69126, Germany
-
LKH-Univ. Klinikum Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Pulmonologie
Graz, 8036, Austria
-
Ordensklinikum Linz GmbH Elisabethinen
Linz, 4020, Austria
-
Royal Free London NHS Foundation Trust
London, United Kingdom
-
Università Degli Studi Di Napoli Federico II Scuola Di Medicina E Chirurgia
Naples, 80131, Italy
-
Universitätsspital Zürich Pulmonale Hypertonie, Klinik für Pneumologie
Zurich, 8091, Switzerland
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Riociguat (oral tablet)
What this could lead to
If successful, this could point toward a treatment option for early-stage pulmonary hypertension, potentially slowing disease progression.
What could go wrong
This trial was terminated early with only 35 participants, so results are limited. Riociguat may not show benefit or could cause side effects like low blood pressure.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.